148 related articles for article (PubMed ID: 32779960)
1. Clinical Follow-up of Patients with Behçet Uveitis after Discontinuation of Infliximab Therapy.
Köse HC; Yalçındağ N
Ocul Immunol Inflamm; 2022 Jan; 30(1):203-207. PubMed ID: 32779960
[TBL] [Abstract][Full Text] [Related]
2. Infliximab therapy in Behçet's uveitis.
Alizadegan F; Yalcinbayir O; Ucan Gunduz G; Pehlivan Y
J Fr Ophtalmol; 2022 Nov; 45(9):1036-1041. PubMed ID: 36150991
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of infliximab in patients with Behçet's disease-associated uveitis.
Yamana S; Hasegawa E; Takeda A; Yawata N; Sonoda KH
Int Ophthalmol; 2023 Mar; 43(3):937-944. PubMed ID: 36057758
[TBL] [Abstract][Full Text] [Related]
4. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome.
Horiguchi N; Kamoi K; Horie S; Iwasaki Y; Kurozumi-Karube H; Takase H; Ohno-Matsui K
Sci Rep; 2020 Dec; 10(1):22227. PubMed ID: 33335139
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study.
Keino H; Okada AA; Watanabe T; Nakayama M; Nakamura T
Ocul Immunol Inflamm; 2017 Feb; 25(1):46-51. PubMed ID: 27767359
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Treatment Results for Behçet Uveitis in Patients Treated with Infliximab and Interferon.
Yalçindag N; Köse HC
Ocul Immunol Inflamm; 2020; 28(2):305-314. PubMed ID: 31268743
[No Abstract] [Full Text] [Related]
7. Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients.
Martín-Varillas JL; Atienza-Mateo B; Calvo-Rio V; Beltrán E; Sánchez-Bursón J; Adán A; Hernández-Garfella M; Valls-Pascual E; Sellas-Fernández A; Ortego N; Maíz O; Torre I; Fernández-Espartero C; Jovani V; Peiteado D; Valle DD; Aurrecoechea E; Caracuel MA; García-González AJ; Álvarez ER; Vegas-Revenga N; Demetrio-Pablo R; Castañeda S; González-Gay MA; Hernández JL; Blanco R;
J Rheumatol; 2021 May; 48(5):741-750. PubMed ID: 33004539
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease.
Gueudry J; Wechsler B; Terrada C; Gendron G; Cassoux N; Fardeau C; Lehoang P; Piette JC; Bodaghi B
Am J Ophthalmol; 2008 Dec; 146(6):837-44.e1. PubMed ID: 19027420
[TBL] [Abstract][Full Text] [Related]
9. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.
Yoshida A; Kaburaki T; Okinaga K; Takamoto M; Kawashima H; Fujino Y
Jpn J Ophthalmol; 2012 Nov; 56(6):536-43. PubMed ID: 23053631
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet's Uveitis: Customizing Therapy according to the Clinical Features.
De Simone L; Invernizzi A; Aldigeri R; Mastrofilippo V; Marvisi C; Gozzi F; Bolletta E; Adani C; Pipitone N; Muratore F; Fontana L; Salvarani C; Cimino L
Ocul Immunol Inflamm; 2022 Feb; 30(2):506-514. PubMed ID: 33021421
[TBL] [Abstract][Full Text] [Related]
11. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
Atienza-Mateo B; Martín-Varillas JL; Calvo-Río V; Demetrio-Pablo R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adan A; Hernández MV; Hernández-Garfella M; Valls-Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; García-Serrano JL; Ortego-Centeno N; Herreras JM; Fonollosa A; Garcia-Aparicio ÁM; Maíz-Alonso O; Blanco A; Torre-Salaberri I; Fernandez-Espartero C; Jovaní V; Peiteado D; Pato E; Cruz J; Férnandez-Cid C; Aurrecoechea E; García-Arias M; Castañeda S; Caracuel-Ruiz MA; Montilla-Morales CA; Atanes-Sandoval A; Francisco F; Insua S; González-Suárez S; Sanchez-Andrade A; Gamero F; Linares Ferrando LF; Romero-Bueno F; García-González AJ; González RA; Muro EM; Carrasco-Cubero C; Olive A; Prior Á; Vázquez J; Ruiz-Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernandez S; Fernández-Carballido C; Rubio-Romero E; Pages FA; Toyos-Sáenz de Miera FJ; Martinez MG; Díaz-Valle D; López Longo FJ; Nolla JM; Álvarez ER; Martínez MR; González-López JJ; Rodríguez-Cundin P; Hernández JL; González-Gay MA; Blanco R
Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Behçet's disease.
Keino H; Watanabe T; Nakayama M; Komagata Y; Fukuoka K; Okada AA
Br J Ophthalmol; 2021 Nov; 105(11):1525-1533. PubMed ID: 32972915
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
14. Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation.
Guzelant G; Ucar D; Esatoglu SN; Hatemi G; Ozyazgan Y; Yurdakul S; Seyahi E; Yazici H; Hamuryudan V
Clin Exp Rheumatol; 2017; 35 Suppl 108(6):86-89. PubMed ID: 29148418
[TBL] [Abstract][Full Text] [Related]
15. An open-label, prospective, single-arm study of switching from infliximab to cyclosporine for refractory uveitis in patients with Behçet's disease in long-term remission.
Ida Y; Takeuchi M; Ishihara M; Shibuya E; Yamane T; Hasumi Y; Kawano S; Kimura I; Mizuki N
Jpn J Ophthalmol; 2021 Nov; 65(6):843-848. PubMed ID: 34586526
[TBL] [Abstract][Full Text] [Related]
16. Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy.
Kawaguchi T; Kawazoe Y; Kamoi K; Miyanaga M; Takase H; Sugita S; Mochizuki M
Jpn J Ophthalmol; 2014 Jan; 58(1):75-80. PubMed ID: 24129677
[TBL] [Abstract][Full Text] [Related]
17. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
[TBL] [Abstract][Full Text] [Related]
18. Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.
Fabiani C; Sota J; Vitale A; Emmi G; Vannozzi L; Bacherini D; Lopalco G; Guerriero S; Venerito V; Orlando I; Franceschini R; Fusco F; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Ocul Immunol Inflamm; 2019; 27(1):34-39. PubMed ID: 29099660
[TBL] [Abstract][Full Text] [Related]
19. Ten-year follow-up of infliximab treatment for uveitis in Behçet disease patients: A multicenter retrospective study.
Takeuchi M; Usui Y; Namba K; Keino H; Takeuchi M; Takase H; Kamoi K; Hase K; Ito T; Nakai K; Maruyama K; Kobayashi E; Mashimo H; Sato T; Ohguro N; Hori J; Okada AA; Sonoda KH; Mizuki N; Goto H
Front Med (Lausanne); 2023; 10():1095423. PubMed ID: 36744150
[TBL] [Abstract][Full Text] [Related]
20. Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis.
Sakai T; Watanabe H; Kuroyanagi K; Akiyama G; Okano K; Kohno H; Tsuneoka H
Br J Ophthalmol; 2013 Mar; 97(3):338-42. PubMed ID: 23314623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
